{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pegylated+interferon+%28Peg-IFN%29+alfa-2a&page=3", "query": { "intervention": "pegylated interferon (Peg-IFN) alfa-2a", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 50, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pegylated+interferon+%28Peg-IFN%29+alfa-2a&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pegylated+interferon+%28Peg-IFN%29+alfa-2a&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T05:41:26.636Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01500772", "title": "Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Alisporivir", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 6, "start_date": "2012-03", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2016-08-01", "last_synced_at": "2026-10-10T05:41:26.636Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01500772" }, { "nct_id": "NCT01054573", "title": "VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "pegylated interferon (Peg-IFN) alfa-2a", "type": "DRUG" }, { "name": "ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Infectious Diseases BVBA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 90, "start_date": "2010-04", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2013-05-08", "last_synced_at": "2026-10-10T05:41:26.636Z", "location_count": 14, "location_summary": "Coronado, California • Los Angeles, California • San Francisco, California + 11 more", "locations": [ { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01054573" }, { "nct_id": "NCT00575224", "title": "Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Chronic Hepatitis C", "Asian Americans", "Novel Genotypes", "Treatment" ], "interventions": [ { "name": "Pegylated interferon and ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pacific Health Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2004-10", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2009-11-25", "last_synced_at": "2026-10-10T05:41:26.636Z", "location_count": 5, "location_summary": "San Diego, California • San Jose, California • Westminster, California + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Westminster", "state": "California" }, { "city": "Houston", "state": "Texas" }, { "city": "Plano", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00575224" }, { "nct_id": "NCT01384383", "title": "GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "GS-5885", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" }, { "name": "PEG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 248, "start_date": "2011-08", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2014-02-03", "last_synced_at": "2026-10-10T05:41:26.636Z", "location_count": 26, "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 20 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01384383" }, { "nct_id": "NCT00420784", "title": "A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa 2a", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 465, "start_date": "2007-02", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2014-08-05", "last_synced_at": "2026-10-10T05:41:26.636Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00420784" }, { "nct_id": "NCT01482390", "title": "A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Ribavirin", "type": "DRUG" }, { "name": "Mericitabine", "type": "DRUG" }, { "name": "Peginterferon Alfa-2a", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Telaprevir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2011-11-30", "completion_date": "2014-01-31", "has_results": false, "last_update_posted_date": "2017-04-24", "last_synced_at": "2026-10-10T05:41:26.636Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Long Beach, California • Sacramento, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482390" }, { "nct_id": "NCT00627926", "title": "A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Pegylated Interferon Alfa 2a", "type": "BIOLOGICAL" }, { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 1095, "start_date": "2008-03", "completion_date": "2010-05", "has_results": true, "last_update_posted_date": "2014-08-08", "last_synced_at": "2026-10-10T05:41:26.636Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00627926" }, { "nct_id": "NCT03719313", "title": "Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis Delta Virus" ], "interventions": [ { "name": "Lonafarnib", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "PEG IFN-alfa-2a", "type": "DRUG" }, { "name": "Placebo Lonafarnib", "type": "DRUG" }, { "name": "Placebo Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eiger BioPharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 407, "start_date": "2018-12-01", "completion_date": "2023-03-24", "has_results": false, "last_update_posted_date": "2023-04-14", "last_synced_at": "2026-10-10T05:41:26.636Z", "location_count": 18, "location_summary": "Fresno, California • Los Angeles, California • Palo Alto, California + 12 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03719313" }, { "nct_id": "NCT01459913", "title": "Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 239, "start_date": "2011-11", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2015-06-10", "last_synced_at": "2026-10-10T05:41:26.636Z", "location_count": 55, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01459913" }, { "nct_id": "NCT00535847", "title": "A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Pegylated interferon alfa 2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 117, "start_date": "2007-10", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2014-08-05", "last_synced_at": "2026-10-10T05:41:26.636Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00535847" } ] }